

## **BARD1 ENTERS AGREEMENT TO DEVELOP A RESEARCH-USE-ONLY AUTOANTIBODY TEST SYSTEM USING PROCARTAPLEX® TECHNOLOGY**

- **BARD1 signs Assay Development Agreement with Thermo Fisher Scientific for Multiplex Research-Use-Only (RUO) Custom Assay Development**
- **A RUO BARD1 autoantibody assay will be developed using ProcartaPlex® Technology for performance on Luminex® instrumentation**
- **The first application of the ProcartaPlex® Technology is to the BARD1-Ovarian test in development for detection of ovarian cancer**

**Perth, Australia, 18 May 2018:** BARD1 Life Sciences Limited (ASX:BD1), a biotechnology company developing non-invasive cancer diagnostics, has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system using ProcartaPlex® Technology for BARD1's research and evaluation.

The agreement defines the development of a multiplex immunoassay in kit format for the semi-quantitative detection of autoantibodies against 20 BARD1 peptides using the ProcartaPlex® Technology for performance on Luminex® instrumentation for BARD1's research and evaluation. The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using the ProcartaPlex® Technology for BARD1's research use. The first application of the ProcartaPlex® Technology is to the BARD1-Ovarian test that BARD1 plans to develop for detection of ovarian cancer.

The custom research assay development project will commence on May-18 and is expected to take approximately **nine** months, with deliverables including Assay Feasibility Report, Development Report, Protocol, Standard Operating Procedures, Assay Validation Report, BARD1-autoantibody kits for research and evaluation, and transfer documentation. If the development project is successful, BARD1 and Thermo Fisher will then discuss the potential for Thermo Fisher to supply research autoantibody kits to BARD1 for its use in research studies.

Dr Leeorne Hinch, BARD1 CEO said; "We are pleased to work with such an experienced partner. The development of a RUO BARD1 autoantibody assay for use on Luminex® instrumentation will be an important milestone for the company, enabling us to initiate clinical testing to evaluate the accuracy of the new multiplex BARD1-Ovarian test for early detection of ovarian cancer in early 2019."

- ENDS -

### **FOR MORE INFORMATION PLEASE CONTACT:**

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

**Dr Leeorne Hinch**  
CEO  
E [leeorne@bard1.com](mailto:leeorne@bard1.com)  
M +61 400 414 416

**ABOUT BARD1 LIFE SCIENCES LTD**

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The development pipeline includes two BARD1 autoantibody tests in development for early detection of lung and ovarian cancers, and a cancer vaccine project at research-stage for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).